CD19 and acute lymphoblastic leukemia: In the RIALTO trial, an open-label, single-arm international study of pediatric patients with CD19-positive r/r BCP-ALL, one of the largest pediatric cohorts (110 patients), most of the patients (n = 98) had ≥5% leukemic blasts in bone marrow at baseline.